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Abstract
Herpes simplex virus type 1 (HSV-1) has two distinct phases of its viral life cycle: lytic and latent.
One viral immediate-early protein that is responsible for determining the balance between
productive lytic replication and reactivation from latency is infected cell protein 0 (ICP0). ICP0 is
a 775-amino acid really interesting new gene (RING)-finger-containing protein that possesses E3
ubiquitin ligase activity, which is required for ICP0 to activate HSV-1 gene expression, disrupt
nuclear domain (ND) 10 structures, mediate the degradation of cellular proteins, and evade the
host cell’s intrinsic and innate antiviral defenses. This article examines our current understanding
of ICP0’s transactivating, E3 ubiquitin ligase, and antihost defense activities and their inter-
relationships to one another. Lastly, we will discuss how these properties of ICP0 may be utilized
as possible targets for HSV-1 antiviral therapies.
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The requirement for ICP0 during viral replication
The importance of infected cell protein 0’s (ICP0’s) role in productive infection and
reactivation from latent infections was initially identified from characterizing the replication
phenotypes of ICP0-null mutants in cell culture. These early reports showed that ICP0
confers a significant growth advantage during replication, especially at low multiplicities of
infection [1–5]. Consistent with cell culture experiments, ICP0-null mutants were
subsequently shown to be attenuated for viral growth [5–8] and impaired for viral
reactivation when equivalent latent infections were established in vivo [9]. Collectively,
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these studies indicated that ICP0 is required for efficient replication and reactivation from
latency.
ICP0: a viral transactivator
One of the first activities described for ICP0 was its ability to activate HSV-1 promoters.
Experiments performed more than 20 years ago using transient transfection and reporter
assays established that ICP0 is capable of transactivating promoters from all three kinetic
classes of HSV-1 genes, including immediate-early, early and late [2,10–14]. Structure–
function studies showed that ICP0’s transactivator function stems from regions located both
in its N-terminal really interesting new gene (RING)-finger and its C-terminus, which
includes a nuclear domain (ND)10 localization signal [15,16], a dimer/multimer motif
[17,18] and a binding site for ubiquitin-specific protease 7 (USP7) (Figure 1) [19]. Deletion
or mutation in one or more of these regions impair, to varying degrees, ICP0’s ability to
fully activate viral gene expression in transient transfection assays and viral infection.
The E3 ubiquitin ligase activity of ICP0
ICP0 mediates its viral transactivator function, in part, through its N-terminal C3HC4 zinc
(Zn2+)-binding RING-finger domain (Figure 1), a structural motif that is conserved in all
ICP0 alphaherpesvirus orthologs (Figure 2) [20,21]. While initial studies that examined
RING-finger domain mutations in ICP0 failed to uncover the biochemical function of this
motif, these studies clearly demonstrated the importance of this domain in viral replication.
Deletion or point mutations within the RING domain not only affect ICP0’s ability to
transactivate reporter gene expression [22], but also its ability to stimulate the initiation of
lytic infection [3,23–25] and reactivate viral genomes from latency [6,8,9,26]. This
impairment is clearly observed in mutants deleted for the RING-finger domain or point
mutations that disable Zn2+ binding, which display growth phenotype properties equivalent
to ICP0-null mutant viruses [3,24].
Insights into the potential biochemical function of ICP0’s RING-finger domain came from a
number of reports showing that ICP0 could interact with components of the ubiquitin–
proteasome pathway during infection. These included ICP0’s ability to form a strong
interaction with USP7 (also known as herpesvirus-associated ubiquitin-specific protease
[HAUSP]) [27–29], to induce the degradation of the catalytic subunit of DNA-dependent
protein kinase (DNA-PKcs) [30,31], and to disrupt ND10 bodies, leading to the degradation
of PML (a core constituent component), its SUMO-modified isoforms and SUMO-modified
Sp100 [32–35]. The capacity of ICP0 to induce the degradation of these proteins occurred in
a RING-finger- and proteasome-dependent manner, indicating that ICP0 could utilize the
ubiquitin–proteasome pathway during viral infection to target specific cellular proteins for
degradation. A number of additional cellular proteins have subsequently been identified as
being targeted for degradation by ICP0, including the centromeric proteins CENP-A, -B and
-C [36–38] and the DNA repair proteins RING-finger protein (RNF)8 and RNF168 [39].
The first evidence demonstrating that ICP0 could act as a viral ubiquitin ligase came from
the observation that ICP0 colocalized with conjugated ubiquitin in the nucleus of infected
cells [40,41]. This attribute was again dependent upon the RING-finger domain of ICP0 and
correlated with its transactivator function. ICP0 mutants that displayed reduced abilities or
completely failed to colocalize with conjugated ubiquitin were similarly impaired in reporter
or viral growth assays [40]. Concurrent with these observations, biochemical studies showed
that purified ICP0 had E3 ubiquitin ligase activity in vitro, catalyzing the formation of
unanchored polyubiquitin chains in a RING-finger-dependent manner [42]. This activity
occurred in an E2-dependent manner, requiring the presence of either UbcH5a (UBE2D1) or
UbcH6a (UBE1E1), two highly homologous E2 ubiquitin-conjugating enzymes. No activity
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was seen when other E2 ubiquitin-conjugating enzymes were tested, including UbcH7
(UBE2L3) and cdc34 (UBE2R1). Consistent with these in vitro observations, UbcH5a and
UbcH6a were also shown to co-localize with ICP0 in the nucleus of transfected cells [42],
and expression of a catalytically inactive UbcH5a mutant reduced ICP0’s ability to degrade
PML [43]. These data support the notion that ICP0 actively recruits ubiquitin-conjugating
enzymes to target cellular proteins for ubiquitination. A number of recent studies have
corroborated the functional importance of ICP0’s RING-finger ubiquitin ligase activity
during HSV-1 infection. First, the mutation of residues within the RING-finger domain of
ICP0 that disrupt UbcH5a binding has been shown to inhibit ICP0’s ability to complement
and reactivate HSV-1 mutant viruses in cell culture [44]. Second, biochemical studies of
other alphaherpesvirus ICP0 RING-finger orthologs, including BICP0 (bovine), EICP0
(equine) and VICP0 (varicella zoster virus), show equivalent E3 ubiquitin ligase activities in
vitro [45,46], which can partially complement the replication of an ICP0-null mutant virus
[46].
ICP0 has also been reported to contain a second ubiquitin ligase domain (herpesvirus
ubiquitin ligase 1 [HUL-1]) within its C-terminus (Figure 1) [47,48]. This second domain
was shown to be required for ICP0 to stimulate the auto-ubiquitination of cdc34 (UBE2R1)
in vitro, consequently leading to a differential change in the stability of cyclins D1 and D3
during infection [49]. However, a subsequent report demonstrated that cdc34 protein levels
were unaltered during HSV-1 infection and that the degradation of cellular cyclins D1 and
D3 occurred in an ICP0-independent manner [50]. Additionally, the HUL-1 region overlaps
with several other functional domains of ICP0 (Figure 1), making it difficult to distinguish
the role of these domains in ICP0’s activities from that proposed for HUL-1. Thus, the role
of HUL-1 as an independent ubiquitin ligase domain in ICP0 has yet to be fully established.
One consequence of ICP0’s RING-finger ubiquitin ligase activity, as with many ubiquitin
ligases, is the propensity for ICP0 to stimulate its own ubiquitination. This activity is readily
detected in vitro [42,51] and can be inhibited or reversed by the addition of USP7 to reaction
mixtures, as the ubiquitin protease activity of USP7 is capable of cleaving off the ubiquitin
chains on ICP0 [51]. Although it is difficult to detect ubiquitinated species of ICP0 during
infection, ICP0 USP7-binding domain mutants are comparatively less stable than wild-type
ICP0. Likewise, depletion of USP7 by RNA interference (RNAi) has also been shown to
decrease the stability and expression levels of ICP0 during infection [51,52]. These data
suggest that ICP0 interacts with USP7 in order to protect itself from auto-ubiquitination,
thereby enhancing its ability to act as a viral transactivator. Interestingly, ICP0 is capable of
catalyzing the ubiquitination of USP7, leading to its proteasomal-dependent degradation
[52]. While the reciprocal biochemical activities of ICP0 and USP7 are relatively clear, the
biological significance remains to be fully elucidated, as point mutations within ICP0 that
disrupt USP7 binding have only a minor impact on lytic viral replication [52]. Nevertheless,
these observations may reflect a potential regulatory feedback mechanism that allows ICP0
to modulate its own activity, a phenotype that may become more apparent when low levels
of ICP0 are expressed, such as during the initial stages of viral reactivation.
ICP0 has also been shown to directly mediate the ubiquitination of a number of other
important cellular proteins, including p53 [53], RNF8 [39] and NF-κB [45], and to stimulate
the ubiquitination of PML in transfected cells [54]. Although the exact mechanism(s) by
which ICP0 mediates the ubiquitination of PML remains to be determined, SUMOylation of
PML plays an important role in ICP0’s ability to target PML for proteasomal degradation
[54]. Therefore, it is likely that ICP0 employs multiple mechanisms (both direct and
indirect) in order to target cellular proteins for ubiquitination. Thus, identifying the cellular
substrates and understanding the biochemistry of ICP0 will likely reveal unique insights into
how HSV-1 lytic and latent infections are regulated.
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ICP0’s E3 ubiquitin ligase activity appears to be regulated by phosphorylation [55]. Tandem
mass spectrometric analysis identified three regions of ICP0 (termed Phos 1, 2 and 3)
containing a total of 11 putative phosphorylation sites (Figure 1) [56]. Mutation of these
sites not only impaired ICP0’s ability to transactivate gene expression (specifically in Phos 1
and 3) [56], but also its ubiquitin ligase activity (Phos 1 and 2) [57]. Mutation of Phos 1
inhibited ICP0’s ability to conjugate ubiquitin and degrade PML and Sp100 in transfection
assays. By contrast, mutation of residues within Phos 2 inhibited ICP0’s ability to degrade
PML, while retaining its ubiquitin ligase activity. However, analysis of these
phosphorylation site mutants in the context of viral infection showed that only mutation of
the Phos 1 region had a defect in viral replication in cell culture. Taken together, these data
suggest that ICP0 phosphorylation is important for efficient viral replication and establishes
a potential mechanism by which ICP0’s E3 ubiquitin ligase activity may be regulated
through post-translational modifications.
Impairment of the host’s antiviral response by ICP0
Due to the functional importance of ICP0 in the biology of HSV-1 replication, a number of
potential mechanisms have been proposed as to how ICP0 works on a molecular level. One
established role for ICP0 during viral infection is its ability to inactivate a number of
components relating to host cell antiviral defense and stress response pathways, including
factors of both intrinsic and innate defenses and one aspect related to acquired immunity
[58–62]. Intrinsic defense, in which many core components are also regulated as part of the
innate response, consists of pre-existing host cell factors that attempt to silence viral gene
expression by making the viral genome functionally inaccessible [58,59,61,62]. Initially, we
will discuss how ICP0 perturbs three intrinsic defense mechanisms, which are ND10s and
their constituent proteins, the chromatinization of the viral genome and the DNA damage
response.
ICP0’s ability to activate viral gene expression is closely associated with its ability to disrupt
ND10s. ND10s are punctate, nuclear suborganelles that contain a variety of nuclear
effectors, such as transcription factors, chromatin remodeling factors and DNA damage
response members, which collectively participate in a number of important cellular
processes, including proliferation, differentiation and antiviral host cell defense (reviewed in
[63]). HSV-1 genomes were initially described as being deposited at ND10s [64];
subsequently, ND10-associated proteins have been observed to disassemble and reform at
sites associated with incoming viral genomes [65]. The prototypic ND10-associated protein
is PML, which nucleates ND10 structures [66]. Other cellular proteins that localize to
ND10s include Sp100, hDaxx and ATRX [66–68]. ICP0 inhibits the cumulative repressive
effects of various ND10-associated proteins by inducing the disruption of ND10 structures
through the degradation of PML, its SUMO-modified isoforms and SUMO-modified Sp100
[33,35], as previously described in this article. This in turn dissociates hDaxx and ATRX
away from viral genomes, preventing these ND10-associated proteins from repressing viral
gene expression [69]. Determining the contribution of specific ND10 constituent proteins in
the biology of HSV-1 replication has primarily been determined by knocking down the
expression of these proteins using RNAi technology. Initially, Everett and co-workers
showed that cells depleted of PML increased the plaque formation efficiency and gene
expression of an ICP0-null mutant virus, but not those of wild-type HSV-1 [70]. Likewise,
depletion of Sp100 had a similar effect on plaque formation and gene expression of an ICP0-
null mutant virus as PML depletion. Combined depletion of both Sp100 and PML
synergistically complemented ICP0-null mutant virus replication [71], indicating that ND10-
associated proteins work cooperatively during intrinsic antiviral defense. Depletion of
hDaxx or ATRX also increased ICP0-null mutant virus titers. Notably, exogenous
expression of an hDaxx RNAi resistant form in hDaxx-depleted cells restored the ability of
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this cell line to repress ICP0-null mutant plaque formation, and this repression was
dependent on hDaxx’s binding partner, ATRX [69]. The fact that an ICP0-null mutant is
only partially complemented by depletion of one or more of these ND10-associated factors
indicates that other cellular factors, which likely include unidentified ND10 constituent
proteins, contribute to the repression of HSV-1 infection, a process that is blocked by the E3
ubiquitin ligase activity of ICP0 during viral infection.
In addition to disrupting ND10s, ICP0 has also been reported to interfere with the
chromatinization of viral DNA. During viral infection, a portion of the viral genome rapidly
associates with histones, and in the absence of ICP0, these histones take on post-
translational modifications indicative of a repressive chromatin structure. ICP0 has been
shown to decrease the amount of histones loaded onto the viral DNA and to promote the
acetylation of the histones that remain, resulting in higher levels of viral transcription
[72,73]. This acetylation of histones directed by ICP0 may be linked to ICP0’s ability to
bind to the class II histone deacetylases, HDAC-4, -5 and -7, affecting the suppressive
effects of these HDACs [74]. However, additional studies will need to be performed in order
to determine whether or not ICP0 has a direct role in viral DNA chromatinization, as
opposed to indirectly influencing this phenotype through its ubiquitin ligase activity.
ICP0 has also been proposed to interact with the cellular factor RE1-silencing transcription
factor corepressor (CoREST) [75]. It was hypothesized that in the absence of ICP0,
CoREST represses HSV-1 transcription and that ICP0 inhibits this process by disrupting the
complex comprised of CoREST, REST and histone acetylases by binding to CoREST
utilizing sequences within its C-terminus (Figure 1). The proposed repressive role of
CoREST and its inactivation by ICP0 were further tested in two subsequent studies. In one
report, a CoREST-binding mutant was still capable of efficiently activating viral expression,
indicating that this ICP0 domain is largely not required for ICP0’s antirepressive function
during lytic infection [76]. A second report demonstrated that depletion of CoREST in cell
culture did not increase the replication efficiency of an ICP0-null mutant virus [77]. These
two reports suggest that ICP0’s interaction with CoREST appears not to be involved in
ICP0’s ability to enhance viral transcription. However, a recent publication has shown that a
dominant-negative (dn)-REST expressed from a wild-type HSV-1 genome during infection
enhanced viral replication in a mouse ocular model, supporting the hypothesis that a
CoREST, REST and histone acetylases complex regulates HSV-1 replication [78]. The role
that the ICP0–CoREST interaction plays in ICP0’s ability to stimulate viral gene expression
in vivo and any indirect affects that dn-REST expression has on the physiology of infected
cells remain to be determined.
While perhaps not traditionally thought of as antiviral in nature, the DNA damage response
also represents a series of pre-existing cellular factors that can serve to restrict the
replication of some viruses. It is unclear as to what exact role the DNA damage response
plays during the HSV-1 life cycle; however, it is apparent that ICP0 is involved in regulating
many aspects relating to this cellular response. Early during infection, ICP0 appears to
initiate damage response pathways by causing activation of the cellular kinase checkpoint
kinase 2 (Chk2) in an ATM-dependent manner, resulting in a cell cycle block at the G2/M
boundary [79]. Chk2 is required for HSV-1 ICP0-mediated G2/M arrest and enhancement of
virus growth. Conversely, ICP0 induces the degradation of another kinase, DNA-PKcs,
disrupting the ability of DNA-PKcs to phosphorylate downstream mediator molecules
regulating DNA repair in response to double-stranded breaks [30]. Furthermore, ICP0 also
targets RNF8 and RNF168 for proteasome-dependent degradation, the activities of which
are necessary for maintaining the presence of DNA repair factors at sites of DNA breaks
[39]. Each of these actions by ICP0 promotes viral growth, as the loss of Chk2 results in
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lower levels of replication, while a loss in DNA-PKcs or depletion of RNF8 or RNF168
partially compensates the replication defect of an ICP0-null mutant virus.
Besides disrupting or degrading pre-existing cellular defenses, ICP0 is also involved in
subverting innate antiviral pathways. Infection by HSV-1 triggers the activation of
interferon (IFN) regulatory factor (IRF)3, which, in the absence of ICP0, translocates to the
nucleus, where it activates the IFN-β promoter, the production of IFN-β and the initiation of
an IFN response [61]. Binding of IFN-β to its cognate receptor results in the activation of the
transcription factors STAT1 and STAT2, which themselves upregulate a class of genes
known as IFN-stimulated genes (ISGs), the products of which have broad antiviral activities.
HSV-1 is typically considered to be an IFN-resistant virus, and ICP0 is critical for this
resistance. In animal models, ICP0-null mutants are attenuated in both their replication and
pathogenesis, while knockout of key IFN-signaling genes such as STAT1 [80] or the IFN-α/β
receptor [81] can relieve the host’s repression of these ICP0 mutants. In cell culture, an
HSV-1 mutant that only expresses ICP0 and no other immediate-early genes is able to
prevent the upregulation of ISGs initiated by viral infection [82]. At present, the effects of
ICP0 on the IFN response appear to be tied to its interaction with IRF3. Following its
disruption of intrinsic nuclear defenses, ICP0 is exported to the cytoplasm and, once there, it
blocks signaling by IRF3 [83]. While the mechanism is unknown, ICP0 is able to either
prevent or reverse the phosphorylation of IRF3 that is necessary for its dimerization, nuclear
translocation and target gene activation [83,84].
Concurrent with its disruption of the IFN response, ICP0 prevents the activation of NF-κB
by Toll-like receptors (TLRs) that detect viral components. ICP0 has been reported to
mediate a reduction in the levels of the TLR-adaptor proteins MyD88 and Mal, to prevent
signaling through TLR-2 [85]. Additionally, ICP0 is able to recruit the normally nuclear
USP7 to the cytoplasm [86]. Once in the cytoplasm, USP7 binds to and removes
polyubiquitin chains from TRAF6 and IKKγ, preventing their activation by TLRs and
degradation, respectively [86]. Both of these proteins are necessary for the nuclear
translocation of NF-κB and the upregulation of NF-κB target genes.
While ICP0 impairs activation of the innate immune response, it is also required for the
successful establishment of a lytic infection in cells in which the IFN response has been
activated prior to infection. In cells pretreated with type I IFNs (such as IFN-β), ICP0-null
mutants can be up to 1000-fold less likely to initiate a lytic infection than wild-type virus
[Smith MC & Davido DJ, Unpublished Data] [87,88].
Expression of ICP0 in trans by either an adenoviral vector or an integrated copy of ICP0 in a
cell line can largely ameliorate the inhibitory effects of type I IFNs on the replication of an
ICP0-null virus [87,89]. Studies performed with mouse embryo fibroblasts derived from
knockout mice indicated that PML was primarily responsible for this effect and that the loss
of PML could compensate for the lack of ICP0 in IFN-treated cells [90]. However, in PML-
depleted human fibroblast cells, IFN-β was still capable of inhibiting the replication of an
ICP0-null mutant, although this effect was diminished [91]. This result indicates that other
ISGs, in addition to PML, likely play a role in the repression of HSV-1 replication by IFN-β.
Furthermore, a study by Halford and coworkers showed that the acute replication of an ICP0
mutant virus was equally repressed in PML-knockout and wild-type mice, suggesting that
the loss of PML (as an ISG) cannot complement the replication of an ICP0 mutant virus in
vivo [80]. Although the report that used PML-knockout mouse embryo fibroblasts and the
studies that used PML-depleted human fibroblasts and mice in vivo appear to come to
different conclusions, PML’s role as a mediator of the IFN response may be dependent upon
the species of the host, homology between PML orthologs and/or the cell types used in these
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studies. It is still unclear how ICP0 enables HSV-1 to replicate in the presence of an
established IFN response.
Lastly, ICP0 has been reported to induce the degradation of the cell surface marker CD83 on
mature dendritic cells, which act as antigen-presenting cells [60]. It is hypothesized that the
elimination of CD83 from mature dendritic cells prevents or diminishes the stimulation of T
cells, allowing HSV-1 to evade one part of the acquired immune response.
Conclusion & future perspective
Virus–host cell interactions determine the outcome (lytic vs latent) of HSV-1 replication.
The ubiquitin ligase activity of ICP0 and its ability to stimulate infection tips the scales in
favor of viral replication, whether during a primary or recurrent infection, making ICP0 an
attractive target for HSV-1 antiviral therapy. ICP0’s ability to enhance viral gene expression
is mediated by the degradation of cellular ‘repressors’ and the inactivation of several cellular
antiviral responses, which include disrupting ND10 domains, impairing viral DNA
chromatinization, altering the host cell’s DNA damage response and impairing IRF3 and
TLR activation (Figure 3). Most of these functions are dependent upon the E3 ubiquitin
ligase activity of ICP0. Ultimately, if novel inhibitors of ICP0’s E3 ubiquitin ligase activity,
transactivating activity and/or ability to subvert host cell defenses could be identified, these
inhibitors would likely maintain the HSV-1 genome in a latent or quiescent state. The
crucial benefit derived from such inhibitors is the prevention or attenuation of recurrent
HSV-1 diseases. Furthermore, understanding the mechanisms by which these inhibitors
function would provide new insights into the roles ICP0 plays during viral infection and in
the biology of HSV-1.
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Infected cell protein 0: a viral transactivator
• Structure–function studies have identified domains in infected cell protein 0
(ICP0), located in its N- and C-termini, that contribute to its transcriptional
activation of viral genes.
The E3 ubiquitin ligase activity of ICP0
• The RING-finger motif of ICP0 is required for efficient viral replication and its
E3 ubiquitin ligase activity.
• Several cellular targets of ICP0-directed degradation regulate its biological
functions.
• The stability of ICP0 is controlled by its interactions with USP7 and auto-
ubiquitination.
• Phosphorylation of ICP0 appears to modulate its transactivating, nuclear domain
(ND)10-disrupting, and E3 ubiquitin ligase activities.
Impairment of the host’s antiviral response by ICP0
• ICP0 impairs intrinsic defenses by several mechanisms, promoting viral
replication.
• ICP0 impairs the activation of the interferon response, mediates resistance to a
pre-existing interferon response and impairs a component of acquired immunity.
Future perspective
• ICP0 plays a pivotal role in the HSV-1 life cycle, making it an attractive target
for designing anti-HSV-1 drugs or therapies.
• Inhibitors of ICP0’s E3 ubiquitin ligase activity, transactivating activity and/or
ability to subvert host cell defenses will likely be effective in preventing
recurrent HSV-1 diseases.
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Figure 1. ICP0 domains
The functional domains of ICP0, which include the RING-finger motif, regions of
phosphorylation (Phos 1–3), NLS, USP7-, ICP0-, CoREST-binding, ND10 localization and
HUL-1 domains. The amino acid positions for each domain are indicated in parentheses.
CoREST: RE1-silencing transcription factor corepressor; HUL: Herpesvirus ubiquitin
ligase; ICP0: Infected cell protein 0; ND10: Nuclear domain 10; NLS: Nuclear localization
signal; RING: Really interesting new gene; USP: Ubiquitin-specific protease.
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Figure 2. Amino acid alignment of ortholog ICP0 RING-finger domains from HSV-1, HSV-2,
bovine herpes virus type-1, equine herpes virus type-1, pseudorabies virus and varicella zoster
virus
Gray vertical bars highlight conserved cysteine and histidine residues within the C3HC4
RING domain that co-ordinate the binding of two zinc atoms. Bracketed numbers refer to
the amino acid positions of the first and last amino acid in each alignment with respect to
their parental polypeptide sequences.
ICP0: Infected cell protein 0; RING: Really interesting new gene.
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Figure 3. Cellular pathways modulated by ICP0 that enhance viral replication
ICP0 inhibits or impairs IRF3 activation, TLR signaling and the chromatinization of viral
DNA and disrupts ND10. For the DNA damage response, ICP0 directly or indirectly
activates (+) Chk2 or inhibits (−) RNF8, RNF168 and DNA-PKcs.
Chk2: Checkpoint kinase 2; DNA-PKcs: DNA-dependent protein kinase; ICP0: Infected cell
protein 0; IRF: Interferon regulatory factor; ND10: Nuclear domain 10; RNF: RING-finger;
TLR: Toll-like receptor.
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